Division of Abdominal Imaging and Intervention, Department of Radiology, Brigham and Women's Hospital, Harvard Medical School, 75 Francis Street, Boston, MA 02115, USA.
J Vasc Interv Radiol. 2011 Apr;22(4):507-14. doi: 10.1016/j.jvir.2010.12.035. Epub 2011 Mar 2.
To develop a technique for guiding percutaneous biopsies of abdominal masses in a positron emission tomography (PET)/computed tomography (CT) scanner, and test its feasibility and safety in patients.
The authors conducted a prospective study in 12 patients who were in need of both a diagnostic (18)F-fluoro-deoxy-D-glucose (FDG) PET/CT scan and a percutaneous biopsy of an abdominal mass, located in the liver (n = 7), presacral soft tissue (n = 2), lymph node (n = 2), and kidney (n = 1). After completion of the PET/CT scan, with the patient remaining on the table, a one-table-position PET/CT scan was obtained with a radiopaque grid in place, and the biopsy procedure was planned. Then, a biopsy needle was placed into the mass using one-table-position CT scan registered to the planning PET scan. Masses were sampled after confirming accurate positioning of the needle tips with a final one-table-position PET/CT scan. Negative results were confirmed independently with follow-up imaging.
All biopsy procedures yielded diagnostic results; nine were positive for malignancy, and three were negative (fibrosis, steatosis, and Escherichia coli infection). One non-FDG-avid mass biopsy yielded a malignant result. Seven masses were either invisible or poorly depicted with unenhanced CT scan, and two masses contained FDG avidity in only a portion of the mass. There were no complications.
Although our data are preliminary, this initial experience suggests that abdominal masses can undergo successful biopsy in a PET/CT scanner. PET/CT guidance may be helpful when performing biopsy on FDG-avid masses that are either not visible with unenhanced CT or are FDG avid in only a portion.
开发一种在正电子发射断层扫描(PET)/计算机断层扫描(CT)扫描仪中引导腹部肿块经皮活检的技术,并在患者中测试其可行性和安全性。
作者对 12 例需要进行诊断性(18)F-氟代脱氧-D-葡萄糖(FDG)PET/CT 扫描和腹部肿块经皮活检的患者进行了前瞻性研究,这些肿块位于肝脏(n=7)、骶前软组织(n=2)、淋巴结(n=2)和肾脏(n=1)。完成 PET/CT 扫描后,患者仍留在检查台上,在放置不透射线网格的情况下进行一次体位 PET/CT 扫描,并计划活检程序。然后,使用与计划 PET 扫描配准的一次体位 CT 扫描将活检针插入肿块中。在用最终一次体位 PET/CT 扫描确认针尖准确定位后,对肿块进行采样。阴性结果通过随访成像进行独立确认。
所有活检程序均获得诊断结果;9 例为恶性,3 例为阴性(纤维化、脂肪变性和大肠埃希菌感染)。1 例非 FDG 摄取肿块活检结果为恶性。7 个肿块在未增强 CT 扫描中不可见或显示不佳,2 个肿块仅在肿块的一部分中摄取 FDG。无并发症发生。
尽管我们的数据是初步的,但这一初步经验表明,腹部肿块可以在 PET/CT 扫描仪中成功进行活检。当对未增强 CT 扫描不可见或仅部分摄取 FDG 的 FDG 摄取性肿块进行活检时,PET/CT 引导可能会有所帮助。